...
首页> 外文期刊>Cancer investigation >MicroRNA and Long Non-Coding RNA in Ovarian Carcinoma: Translational Insights and Potential Clinical Applications
【24h】

MicroRNA and Long Non-Coding RNA in Ovarian Carcinoma: Translational Insights and Potential Clinical Applications

机译:卵巢癌中的MicroRNA和长非编码RNA:翻译的见解和潜在的临床应用。

获取原文
获取原文并翻译 | 示例

摘要

Reliable biomarkers for the detection of early ovarian carcinoma are currently unavailable. MicroRNA and long non-coding RNA may be important in cancer initiation and progression by regulating gene expression through post-transcriptional mechanisms. MicroRNAs, such as miR-26a and miR-132, have been investigated as novel biomarkers for diagnosis, prognosis, monitoring of therapeutic response, and therapeutic targets in ovarian carcinomas. Some long non-coding RNAs, such as H19 and UCA1, may be involved in the pathogenesis of ovarian carcinomas. MicroRNA and long non-coding RNA have potential clinical utility in the diagnosis of ovarian cancer and predicting prognosis, metastasis, recurrence, and response to therapy.
机译:目前尚无用于检测早期卵巢癌的可靠生物标志物。通过转录后机制调节基因表达,MicroRNA和长非编码RNA在癌症的发生和发展中可能很重要。已经研究了诸如miR-26a和miR-132的MicroRNA,作为诊断,预后,监测治疗反应和卵巢癌治疗靶标的新型生物标志物。一些长的非编码RNA,例如H19和UCA1,可能与卵巢癌的发病机制有关。 MicroRNA和长的非编码RNA在卵巢癌的诊断以及预测预后,转移,复发和对治疗的反应方面具有潜在的临床用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号